Neuropace Inc (NPCE) - News Archive

Investigative Alert: Pomerantz Law Firm Probes Potential Investor Claims Against NeuroPace, Inc. Amidst Robust Revenue GrowthIn a notable development from the financial and legal landscapes, Pomerantz LLP is initiating...

NeuroPace Completes Strategic Share Repurchase, Strengthens Market Position MOUNTAIN VIEW, Calif. Feb. 20, 2025 NeuroPace, Inc. (NASDAQ: NPCE), a cutting-edge medical device company dedicated to improving the lives of i...

NeuroPace Secures $74.8 Million Through Successful Public Offering: A Strategic Move Amidst Growing Demand for Neuromodulation SolutionsOn February 18, 2025, NeuroPace, Inc. (Nasdaq: NPCE), a leader in neuromodulation t...

NeuroPace s Strategic Maneuvers: Navigating the Market for Epilepsy SolutionsIn a notable display of market confidence and strategic foresight, NeuroPace, Inc. a pioneering force in the development of innovative solutio...

Advancements in Neuromodulation: NeuroPace s RNS System Demonstrates Promising Outcomes in Focal Epilepsy : The advent of neuromodulation technologies has ushered in innovative therapeutic modalities for managing drug-r...

In a significant shift in its corporate strategy, NeuroPace Inc. a leader in the development of innovative neurostimulation treatments, has recently appointed an experienced people leader as its Vice President of Human...

NeuroPace, a leading medical technology company specializing in neuromodulation therapies, announced its preliminary unaudited revenue for the fourth quarter and full year 2023, along with some important business update...

NeuroPace Inc., a leading pioneer in neurostimulation technology, has recently announced the successful completion of patient enrollment in its groundbreaking NAUTILUS Pivotal Study. NAUTILUS is the first-ever pivotal c...